Please use this identifier to cite or link to this item:
https://doi.org/10.1002/ajh.23213
DC Field | Value | |
---|---|---|
dc.title | Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group | |
dc.contributor.author | Tse, E. | |
dc.contributor.author | Gill, H. | |
dc.contributor.author | Loong, F. | |
dc.contributor.author | Kim, S.J. | |
dc.contributor.author | Ng, S.-B. | |
dc.contributor.author | Tang, T. | |
dc.contributor.author | Ko, Y.-H. | |
dc.contributor.author | Chng, W.-J. | |
dc.contributor.author | Lim, S.-T. | |
dc.contributor.author | Kim, W.S. | |
dc.contributor.author | Kwong, Y.-L. | |
dc.date.accessioned | 2016-07-08T07:19:42Z | |
dc.date.available | 2016-07-08T07:19:42Z | |
dc.date.issued | 2012-07 | |
dc.identifier.citation | Tse, E., Gill, H., Loong, F., Kim, S.J., Ng, S.-B., Tang, T., Ko, Y.-H., Chng, W.-J., Lim, S.-T., Kim, W.S., Kwong, Y.-L. (2012-07). Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. American Journal of Hematology 87 (7) : 663-668. ScholarBank@NUS Repository. https://doi.org/10.1002/ajh.23213 | |
dc.identifier.issn | 03618609 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/125295 | |
dc.description.abstract | Enteropathy-associated T-cell lymphoma (EATL) is a rare primary gastrointestinal T-cell lymphoma. A multicenter study from the Asia Lymphoma Study Group identified 38 EATL patients within a 19-year period. All cases were type II EATL. Men were affected twice as common as women, at a median age of 59 (23-89) years. None had a history of celiac disease. The sites of involvement were small bowel and stomach (5%), small bowel (63%), small and large bowel (16%), and large bowel (18%). Common presenting features were bowel perforation (34%), pain (32%), and obstruction (21%). Lymphomas showed monomorphic neoplastic lymphoid infiltrates that were CD3 + (100%), CD56 + (91%), TIA-1 + (96%), CD4 -CD8 + (63%), CD4 +CD8 + (19%), CD4 -CD8 - (16%), and CD4 +CD8 - (3%). Epstein Barr virus was demonstrable in three cases. Despite chemotherapy and/or surgical resection, the overall response and complete response rates were poor at 46% and 38%. The median overall survival (OS) was 7 months and progression-free-survival (PFS) 1 month. Five patients underwent hematopoietic stem cell transplantation all were alive. Age and the prognostic index for peripheral T-cell lymphoma were not prognostically significant. Good performance status was associated with better OS (P = 0.03), and response to initial treatment led to better OS and PFS (P < 0.001). © 2012 Wiley Periodicals, Inc. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1002/ajh.23213 | |
dc.source | Scopus | |
dc.type | Article | |
dc.contributor.department | PATHOLOGY | |
dc.contributor.department | MEDICINE | |
dc.contributor.department | DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE | |
dc.description.doi | 10.1002/ajh.23213 | |
dc.description.sourcetitle | American Journal of Hematology | |
dc.description.volume | 87 | |
dc.description.issue | 7 | |
dc.description.page | 663-668 | |
dc.description.coden | AJHED | |
dc.identifier.isiut | 000305209700004 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.